Trial in Adult Participants With Spinocerebellar Ataxia (SCA)
Public ClinicalTrials.gov record NCT02960893. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Participants With Spinocerebellar Ataxia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary purpose of this study was to compare the efficacy of BHV-4157 (Troriluzole) 140 milligrams (mg) once daily versus placebo after 8 weeks of treatment in participants with spinocerebellar ataxia (SCA).
Study identification
- NCT ID
- NCT02960893
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 141 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 15, 2016 (Actual)
- Primary completion
- Aug 18, 2017 (Actual)
- Completion
- Sep 20, 2024 (Actual)
- Last update posted
- Oct 8, 2025
2016 – 2024
United States locations
- U.S. sites
- 18
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| St. Joseph's Hospital and Medical Center | Phoenix | Arizona | 85013 | — |
| CNS Trial | Long Beach | California | 90806 | — |
| University of California, Los Angeles | Los Angeles | California | 90095 | — |
| University of California, San Francisco | San Francisco | California | 94158 | — |
| University of Colorado Denver | Denver | Colorado | 80045 | — |
| University of Florida | Gainesville | Florida | 32611 | — |
| University of South Florida | Tampa | Florida | 33612 | — |
| Emory University | Atlanta | Georgia | 30329 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Johns Hopkins University | Baltimore | Maryland | 21287 | — |
| Harvard University (Massachusetts General Hospital) | Boston | Massachusetts | 02114 | — |
| Harvard University (Beth Israel Deaconess Medical Center) | Boston | Massachusetts | 02215 | — |
| University of Michigan | Ann Arbor | Michigan | 48105 | — |
| Columbia University | New York | New York | 10032 | — |
| University of Rochester Medical Center | Rochester | New York | 14642 | — |
| University of Texas Southwestern | Dallas | Texas | 75390 | — |
| Houston Methodist Research Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02960893, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 8, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02960893 live on ClinicalTrials.gov.